Tetrahydrocannabinol Facts
Cannabinoid;
Description
THC (delta-9-tetrahydrocannabinol) — weed, pot, marijuana — is a cannabinoid of the terpenophenolic class. It activates cannabinoid receptors in the brain, suppressing neurotransmitter release and producing its characteristic shifts in mood, perception, and memory.
Subjective effects include euphoria, appetite stimulation, time alteration, relaxation, and anxiety at higher doses. The experience is defined by its sensitivity to context — the same dose can produce warm calm in one setting and anxious self-consciousness in another.[1]
About 9% of users develop cannabis use disorder, rising to 17% in adolescence;[2] no confirmed human fatality from overdose alone has been recorded.[3][4] The primary danger is psychiatric — daily high-potency use carries an odds ratio of 4.8 for psychotic disorder,[5] amplified by early onset and genetic vulnerability.
Dose and durationby route · individual sensitivity varies
Starts in 30 – 90 minLasts 4 – 12 hoursAfter-effects 6 – 24 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Physical dependence
- Moderate
- Psychological dependence
- Moderate
- Withdrawal
- Moderate
- Compulsive redosing
- Low
Tolerance
- Builds
- Moderate
- Fully resets after
- 28 days
- Carries over to
- synthetic cannabinoids;
endocannabinoids; other CB1 agonists
Effectslikely at a common dose
- Perception
- Dreaming suppression;
Music enhancement; +15 possible, including Spatial disorientation, Vestibular distortion - Body
- Abnormal heartbeat;
Appetite enhancement; Body high; Dry mouth; Heart rate perception changes; Laughter fits; Motor control impairment; Muscle relaxation; Pain suppression; Sedation; +14 possible, including Dizziness, Insomnia, Nausea - Thinking
- Aesthetic enhancement;
Cognitive euphoria; Cognitive impairment; Decision impairment; Humor enhancement; Information processing suppression; Memory fragmentation; Memory suppression; Thought connectivity; Thought disorganization; +22 possible, including Analysis suppression, Confusion, Delusions of sobriety - Feeling
- Euphoria;
+8 possible, including Anxiety, Paranoia, Dysphoria - Self
- none likely · 10 possible, including Craving, Depersonalization, Derealization
- Time
- Time alteration;
+2 possible, including Temporal disorientation - Awareness
- none likely · 1 possible
Who shouldn't take it
Combinations60 recorded
Seek help immediately if
Natural cannabis rarely causes a medical emergency — "greening out" is: pale/sweaty skin, dizziness, nausea or vomiting, anxiety or panic, rapid heartbeat, feeling faint — and usually passes with rest.
Seek emergency help for these — far more likely with synthetic cannabinoids ("spice" / K2):
- Seizures
- Severe chest pain; very fast or irregular heartbeat
- Unresponsiveness or extreme drowsiness
- Severe agitation, aggression, or psychosis
- Repeated vomiting; difficulty breathing
What to do
- Sit or lie them down somewhere calm, cool, and quiet
- Reassure them — cannabis panic and "greening out" pass with time
- Offer sips of water; a little sugar can help if they feel faint
- Recovery position if nauseated, drowsy, or vomiting
- Stay with them and monitor
- For seizures, chest pain, unresponsiveness, or severe agitation, call emergency services
Natural cannabis "greening out" resolves with rest, calm, and time, with no lasting harm. Synthetic cannabinoids are unpredictable and can cause seizures, cardiac events, kidney injury, and severe agitation that needs emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, et al. (2009) Cannabis and anxiety: a critical review of the evidence — Human Psychopharmacology Clinical and Experimental doi:10.1002/hup.1048
- [2]^Hasin DS (2017) US Epidemiology of Cannabis Use and Associated Problems — Neuropsychopharmacology doi:10.1038/npp.2017.198
- [3]^Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS (1990) Cannabinoid receptor localization in brain. — Proceedings of the National Academy of Sciences doi:10.1073/pnas.87.5.1932
- [4]^Grotenhermen F (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids — Clinical Pharmacokinetics doi:10.2165/00003088-200342040-00003
- [5]^Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, et al. (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. — The Lancet Psychiatry doi:10.1016/s2215-0366(19)30048-3